Trending

COPD

Novartis builds case for asthma drugs to challenge GSK

Novartis builds case for asthma drugs to challenge GSK

Novartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take

X

Novartis builds case for asthma drugs to challenge GSK

https://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/

Boehringer looks to enhance COPD care with new registry

Boehringer looks to enhance COPD care with new registry

Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience

X

Boehringer looks to enhance COPD care with new registry

https://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/

Study aims to identify digital predictors of COPD exacerbations

Study aims to identify digital predictors of COPD exacerbations

Spire Health has launched a research study on COPD exacerbations using continuous respiratory sensors to assess adherence and

X

Study aims to identify digital predictors of COPD exacerbations

https://pharmaphorum.com/news/study-aims-to-identify-digital-predictors-of-copd-exacerbations/

Mylan launches Advair generic at 70% discount in US

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the

X

Mylan launches Advair generic at 70% discount in US

https://pharmaphorum.com/news/mylan-launches-advair-generic-at-70-discount-in-us/

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic

X

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

https://pharmaphorum.com/news/astrazeneca-copd-bevespi-aerosphere/

AZ COPD drug fails to match GSK rival after disappointing launch

AZ COPD drug fails to match GSK rival after disappointing launch

AstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in

X

AZ COPD drug fails to match GSK rival after disappointing launch

https://pharmaphorum.com/news/az-copd-drug-fails-match-gsk-rival/

GSK’s Nucala unlikely to get COPD use after panel vote

GSK’s Nucala unlikely to get COPD use after panel vote

FDA due to make decision in September

X

GSK’s Nucala unlikely to get COPD use after panel vote

https://pharmaphorum.com/news/gsks-nucala-unlikely-to-get-copd-use-after-panel-vote/

NICE restricts use of antibiotics in draft COPD guidance

NICE restricts use of antibiotics in draft COPD guidance

NICE has published draft guidance restricting use of antibiotics in patients with chronic obstructive pulmonary disease (COPD), as

X

NICE restricts use of antibiotics in draft COPD guidance

https://pharmaphorum.com/news/nice-restricts-use-of-antibiotics-in-draft-copd-guidance/

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

X

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com